These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 18793417)

  • 21. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
    Wang H; Li T; Chen S; Gu Y; Ye S
    Arthritis Rheumatol; 2015 Dec; 67(12):3190-200. PubMed ID: 26245802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis.
    Puapatanakul P; Chansritrakul S; Susantitaphong P; Ueaphongsukkit T; Eiam-Ong S; Praditpornsilpa K; Kittanamongkolchai W; Avihingsanon Y
    Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31597273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of Interferon and Proinflammatory Cyto/chemokines in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus.
    Steiman AJ; Gladman DD; Ibañez D; Noamani B; Landolt-Marticorena C; Urowitz MB; Wither JE
    J Rheumatol; 2015 Dec; 42(12):2318-26. PubMed ID: 26568589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct Functions of Autoantibodies Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine Autoantibodies in Common Rheumatic Diseases.
    Gupta S; Tatouli IP; Rosen LB; Hasni S; Alevizos I; Manna ZG; Rivera J; Jiang C; Siegel RM; Holland SM; Moutsopoulos HM; Browne SK
    Arthritis Rheumatol; 2016 Jul; 68(7):1677-87. PubMed ID: 26815287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum and urine TNF-like weak inducer of apoptosis, monocyte chemoattractant protein-1 and neutrophil gelatinase-associated lipocalin as biomarkers of disease activity in patients with systemic lupus erythematosus.
    Mirioglu S; Cinar S; Yazici H; Ozluk Y; Kilicaslan I; Gul A; Ocal L; Inanc M; Artim-Esen B
    Lupus; 2020 Apr; 29(4):379-388. PubMed ID: 32041504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies.
    Hua J; Kirou K; Lee C; Crow MK
    Arthritis Rheum; 2006 Jun; 54(6):1906-16. PubMed ID: 16736505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathways of impending disease flare in African-American systemic lupus erythematosus patients.
    Munroe ME; Vista ES; Merrill JT; Guthridge JM; Roberts VC; James JA
    J Autoimmun; 2017 Mar; 78():70-78. PubMed ID: 28162788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abnormal expression of chemokine receptors on T-cells from patients with systemic lupus erythematosus.
    Eriksson C; Eneslätt K; Ivanoff J; Rantapää-Dahlqvist S; Sundqvist KG
    Lupus; 2003; 12(10):766-74. PubMed ID: 14596426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of calreticulin expression with disease activity and organ damage in systemic lupus erythematosus patients.
    Wang Y; Xie J; Liu Z; Fu H; Huo Q; Gu Y; Liu Y
    Exp Ther Med; 2017 May; 13(5):2577-2583. PubMed ID: 28565882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.
    Kim AHJ; Strand V; Sen DP; Fu Q; Mathis NL; Schmidt MJ; Bruchas RR; Staten NR; Olson PK; Stiening CM; Atkinson JP
    Arthritis Rheumatol; 2019 Mar; 71(3):420-430. PubMed ID: 30294950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis.
    Mok CC; Soliman S; Ho LY; Mohamed FA; Mohamed FI; Mohan C
    Arthritis Res Ther; 2018 Jan; 20(1):6. PubMed ID: 29325582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis.
    Liu X; Mayes MD; Tan FK; Wu M; Reveille JD; Harper BE; Draeger HT; Gonzalez EB; Assassi S
    Arthritis Rheum; 2013 Jan; 65(1):226-35. PubMed ID: 23055137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction between oxidative stress and chemokines: possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis.
    Shah D; Wanchu A; Bhatnagar A
    Immunobiology; 2011 Sep; 216(9):1010-7. PubMed ID: 21601309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon-γ-inducible chemokines in systemic lupus erythematosus.
    Elia G
    Clin Ter; 2015; 166(1):e41-6. PubMed ID: 25756266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blockade of interferon-γ normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus.
    Welcher AA; Boedigheimer M; Kivitz AJ; Amoura Z; Buyon J; Rudinskaya A; Latinis K; Chiu K; Oliner KS; Damore MA; Arnold GE; Sohn W; Chirmule N; Goyal L; Banfield C; Chung JB
    Arthritis Rheumatol; 2015 Oct; 67(10):2713-22. PubMed ID: 26138472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus.
    Oke V; Gunnarsson I; Dorschner J; Eketjäll S; Zickert A; Niewold TB; Svenungsson E
    Arthritis Res Ther; 2019 Apr; 21(1):107. PubMed ID: 31036046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
    Mok CC; Ho LY; Cheung MY; Yu KL; To CH
    Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus.
    Rose T; Grützkau A; Hirseland H; Huscher D; Dähnrich C; Dzionek A; Ozimkowski T; Schlumberger W; Enghard P; Radbruch A; Riemekasten G; Burmester GR; Hiepe F; Biesen R
    Ann Rheum Dis; 2013 Oct; 72(10):1639-45. PubMed ID: 23117242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fas promoter -670 polymorphism is associated with development of anti-RNP antibodies in systemic lupus erythematosus.
    Lee YH; Kim YR; Ji JD; Sohn J; Song GG
    J Rheumatol; 2001 Sep; 28(9):2008-11. PubMed ID: 11550967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus.
    Mende R; Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Lin E; Chang J; Hoi AY; Morand EF; Harris J; Lang T
    Front Immunol; 2018; 9():1250. PubMed ID: 29930551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.